review article | Q7318358 |
meta-analysis | Q815382 |
scholarly article | Q13442814 |
P356 | DOI | 10.1002/14651858.CD005225.PUB3 |
P698 | PubMed publication ID | 23235621 |
P50 | author | Daniel M Pastula | Q63827259 |
P2093 | author name string | Dan H Moore | |
Richard S Bedlack | |||
P2860 | cites work | Creatine for amyotrophic lateral sclerosis/motor neuron disease | Q24234800 |
Creatine for amyotrophic lateral sclerosis/motor neuron disease | Q24244631 | ||
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis | Q29619074 | ||
Amyotrophic lateral sclerosis | Q29619516 | ||
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. | Q30440341 | ||
Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease | Q33631319 | ||
Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases | Q33917550 | ||
The creatine-creatine phosphate energy shuttle | Q34194064 | ||
ALSFRS-R. | Q34362989 | ||
The epidemiology of motor neuron diseases: a review of recent studies | Q34417934 | ||
Recent advances in amyotrophic lateral sclerosis research | Q35036503 | ||
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. | Q35476043 | ||
Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment | Q36488392 | ||
Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q37613342 | ||
Survival of patients with amyotrophic lateral sclerosis in a population-based registry | Q38473621 | ||
The epidemiology of ALS in Modena, Italy | Q39642568 | ||
A simple analysis of the "phosphocreatine shuttle" | Q40176885 | ||
A clinical trial of creatine in ALS. | Q40469445 | ||
Regression Models and Life-Tables (with discussion) | Q41363019 | ||
Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis | Q43744283 | ||
Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. | Q43777132 | ||
Direct antioxidant properties of creatine | Q43846466 | ||
A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. | Q43991574 | ||
No effect of creatine on respiratory distress in amyotrophic lateral sclerosis | Q44025613 | ||
A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 | ||
Factors associated with survival in the National Registry of Veterans with ALS. | Q44903303 | ||
Functional outcome measures as clinical trial endpoints in ALS. | Q45158825 | ||
Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity | Q46977833 | ||
Bipap improves survival and rate of pulmonary function decline in patients with ALS. | Q48758870 | ||
Prognosis in amyotrophic lateral sclerosis: a population-based study. | Q51950008 | ||
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 | ||
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 | ||
Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period | Q58125373 | ||
Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function | Q72718273 | ||
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group | Q72759362 | ||
The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register | Q72843336 | ||
Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998 | Q74506333 | ||
Amyotrophic lateral sclerosis: early predictors of prolonged survival | Q83988720 | ||
P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
P577 | publication date | 2012-12-12 | |
P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
P1476 | title | Creatine for amyotrophic lateral sclerosis/motor neuron disease |
Q34554820 | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? |
Q26777929 | Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis |
Q37651130 | Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice |
Q38691246 | Creatine for neuroprotection in neurodegenerative disease: end of story? |
Q24187191 | Creatine for women in pregnancy for neuroprotection of the fetus |
Q61808045 | Emergent Prophylactic, Reparative and Restorative Brain Interventions for Infants Born Preterm With Cerebral Palsy |
Q90531525 | Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions |
Q92813735 | Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment |
Q36679757 | Intraspinal stem cell transplantation for amyotrophic lateral sclerosis |
Q62785679 | Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
Q35630224 | Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review |
Q38772250 | Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. |
Q89645812 | The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future |
Q52673338 | Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. |
Q38188662 | Why is ALS so Difficult to Treat? |
Search more.